Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease | Zendy

Frederick E. Dewey | Zendy; Viktoria Gusarova | Zendy; Richard L. Dunbar | Zendy; Colm O’Dushlaine | Zendy; Claudia Schurmann | Zendy; Omri Gottesman | Zendy; Shane McCarthy | Zendy; Cristopher V. Van Hout | Zendy; Shan Bruse | Zendy; Hayes M. Dansky | Zendy; Joseph B. Leader | Zendy; Michael F. Murray | Zendy; Marylyn D. Ritchie | Zendy; H. Lester Kirchner | Zendy; Lukas Habegger | Zendy; Alex Lopez | Zendy; John S. Penn | Zendy; An Sha Zhao | Zendy; Weiping Shao | Zendy; Neil Stahl | Zendy; Andrew Murphy | Zendy; Sara Hamon | Zendy; Aurelie Bouzelmat | Zendy; Rick Zhang | Zendy; Brad Shumel | Zendy; Robert Pordy | Zendy; Daniel A. Gipe | Zendy; Gary Herman | Zendy; Wayne HueyHerng Sheu | Zendy; ITe Lee | Zendy; KaeWoei Liang | Zendy; Xiuqing Guo | Zendy; Jerome I. Rotter | Zendy; YiiDer I. Chen | Zendy; William E. Kraus | Zendy; Svati H. Shah | Zendy; Scott M. Damrauer | Zendy; Aeron Small | Zendy; Daniel J. Rader | Zendy; Anders Berg Wulff | Zendy; Børge G. Nordestgaard | Zendy; Anne TybjærgHansen | Zendy; Anita M. van den Hoek | Zendy; P. Hans | Zendy; David H. Ledbetter | Zendy; David J. Carey | Zendy; John D. Overton | Zendy; Jeffrey G. Reid | Zendy; William J. Sasiela | Zendy; Poulabi Banerjee | Zendy; Alan R. Shuldiner | Zendy; Ingrid B. Borecki | Zendy; Tanya M. Teslovich | Zendy; George D. Yancopoulos | Zendy; Scott Mellis | Zendy; Jesper Gromada | Zendy; Aris Baras | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease

Author(s) -

Frederick E. Dewey,

Viktoria Gusarova,

Richard L. Dunbar,

Colm O’Dushlaine,

Claudia Schurmann,

Omri Gottesman,

Shane McCarthy,

Cristopher V. Van Hout,

Shan Bruse,

Hayes M. Dansky,

Joseph B. Leader,

Michael F. Murray,

Marylyn D. Ritchie,

H. Lester Kirchner,

Lukas Habegger,

Alex Lopez,

John S. Penn,

An Sha Zhao,

Weiping Shao,

Neil Stahl,

Andrew Murphy,

Sara Hamon,

Aurelie Bouzelmat,

Rick Zhang,

Brad Shumel,

Robert Pordy,

Daniel A. Gipe,

Gary Herman,

Wayne HueyHerng Sheu,

ITe Lee,

KaeWoei Liang,

Xiuqing Guo,

Jerome I. Rotter,

YiiDer I. Chen,

William E. Kraus,

Svati H. Shah,

Scott M. Damrauer,

Aeron Small,

Daniel J. Rader,

Anders Berg Wulff,

Børge G. Nordestgaard,

Anne TybjærgHansen,

Anita M. van den Hoek,

P. Hans,

David H. Ledbetter,

David J. Carey,

John D. Overton,

Jeffrey G. Reid,

William J. Sasiela,

Poulabi Banerjee,

Alan R. Shuldiner,

Ingrid B. Borecki,

Tanya M. Teslovich,

George D. Yancopoulos,

Scott Mellis,

Jesper Gromada,

Aris Baras

Publication year - 2017

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1612790

Subject(s) - medicine , cholesterol , disease , lipoprotein , endocrinology , atherosclerotic cardiovascular disease , genetic variants , gene , genetics , biology , genotype

Loss-of-function variants in the angiopoietin-like 3 gene (ANGPTL3) have been associated with decreased plasma levels of triglycerides, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol. It is not known whether such variants or therapeutic antagonism of ANGPTL3 are associated with a reduced risk of atherosclerotic cardiovascular disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research